Option Exercise Period Clause Samples

Option Exercise Period. 4.1 The Purchaser shall be authorized to exercise the Option at any time during the Option Exercise Period which shall start on the date this Agreement is signed and which will end within a period of four (4) years calculated from the aforementioned date.

Option Exercise Period. Check One:

Option Exercise Period. Options expire and are void unless exercised on or before _________________. NOTICE OF EXERCISE The undersigned hereby notifies Towne Services, Inc. (the "Company") of this election to exercise the undersigned's stock option to purchase ______ shares of the Company's Common Stock, no par value (the "Common Stock"), pursuant to the Stock Option Agreement (the "Agreement") between the undersigned and the Company dated ________________. Accompanying this Notice is (1) a certified or a cashier's check in the amount of $________________ payable to the Company, and/or (2) _______________ shares of the Company's Common Stock presently owned by the undersigned and duly endorsed or accompanied by stock transfer powers, having an aggregate Fair Market Value as of the date hereof of $__________________, such amounts being equal, in the aggregate, to the purchase price per share set forth in Section 3 of the Agreement multiplied by the number of shares being purchased hereby (in each instance subject to appropriate adjustment pursuant to Section 7 of the Agreement).

Option Exercise Period. In addition to the Separation Benefit, described above in Section 3 and as further consideration for the Releases granted herein, JANICIK shall be permitted to extend the expiration date on options for 77,494 shares (the "Extended Options") from ninety (90) days after Termination Date to the earlier of (i) eighteen (18) months from his resignation as a consultant to EMPLOYER, or (ii) the original expiration date of the option (the "Extended Expiration Date"), subject to Board approval and contingent upon EMPLOYER being awarded Task Order #2 for the MDA project. Notwithstanding the foregoing, if EMPLOYER is not awarded Task Order #2 for the MDA project through no fault of JANICIK, i.e., JANICIK used his best efforts to assist EMPLOYER in obtaining Task Order #2, EMPLOYER shall extend the expiration date on options for 77,494 shares from ninety (90) days after Termination Date to the earlier of (i) sixty (60) days from notification by MDA to EMPLOYER that Task Order #2 will not be awarded, or (ii) the original expiration date of the option. Any portion of the Extended Options not purchased at the Extended Expiration Date will be forfeited. All other options held by JANICIK as of June 18, 2004 shall cease to vest as of that date. JANICIK understands and acknowledges that the Extended Options will no longer be eligible for preferential tax treatment as Incentive Stock Options (ISOs) under Section 422 of the Internal Revenue Code of 1986, as amended, with respect to any exercise occurring after the Resignation Date, and he will be taxed upon exercise of the Extended Options after such date as though they had been issued as Non-Qualified Stock Options (NQLs).

Option Exercise Period. AVEO shall deliver the Data Package from the first Proof of Concept Study to Biogen Idec and an initial Development Plan no later than [**] after the last visit of the last patient to be dosed in such Proof of Concept Study. During the [**] following delivery of the Data Package, (i) Biogen Idec may request, and AVEO will provide to Biogen Idec, any other data and information in AVEO’s possession and Control (and AVEO shall make reasonable efforts to procure or produce such other data and information that is not in AVEO’s possession and Control) as Biogen Idec may reasonably request in connection with its review of the Data Package (the “Supplemental Information”), (ii) the Parties shall meet in good faith to discuss Biogen Idec’s comments to the initial Development Plan in accordance with Section 2.9, (iii) AVEO will deliver to Biogen Idec copies of any AVEO In-Licenses entered into after the Effective Date, and (iv) AVEO will deliver to Biogen Idec a reasonably detailed statement of Pre-Option Exercise Phase 3 Manufacturing Costs actually incurred by AVEO and its Affiliates as of such date and reasonably expected to be incurred prior to the end of the Option Exercise Period. The Option shall be exercisable by Biogen Idec at any time during the period commencing on the Effective Date and ending on the later of (i) [**] after delivery of the Data Package, or (ii) [**] after the last to be delivered of the Supplemental Information (the “Option Exercise Period”).

Option Exercise Period. During the Option Exercise Period, AVEO shall be free to publish the results of Development carried out on the Licensed Product.

Option Exercise Period. The Option may be exercised by the Optionee, in whole or in part (but in no case in tranches of less than 100,000 shares), at any time from the date hereof until March 9, 2012 (the “Termination Date”) and shall terminate on the Termination Date unless exercised by the Optionee prior thereto.

Option Exercise Period. With respect to any Development Polypeptide, each Option may be exercised by AstraZeneca during the period commencing on the date that a Development Polypeptide and associated Product Candidate is included in the Development Pool until [***] days after the [***] Option Agreement Effective Date for the first Product Candidate (or any other Collaboration mRNA Construct) [***] such Development Polypeptide (the applicable “Option Exercise Period” for such Development Polypeptide), subject to Section 6.9.

Option Exercise Period. Genzyme shall exercise an Option, if at all, by properly delivering a complete Option Exercise Notice in respect of such Option to Voyager at any time during the respective Option Exercise Period for such Option.